Mineralys Therapeutics, Inc.
Financials
Valuation Metrics
Mineralys Therapeutics, Inc.'s Market Cap is $1.37B. At end of 2025 it was $2.92B. Ranked #2130 of 3,118 in US market (top 68%), #824 of 1,474 on NASDAQ (top 56%), #151 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 57%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.37B | US#2,130/3,118 Sec#151/265 |
| Revenue | $0.00 | US#2,858/3,118 Sec#193/265 |
| Net Income | $-350M | US—/3,118 Sec—/265 |
| Total Assets | $668M | US#2,649/3,118 Sec#137/265 |
| Net Assets | $551M | US#2,155/3,118 Sec#100/265 |
| Employees | 76 | US#2,655/3,118 Sec#192/265 |
| Value | ||
| P/B | 2.49x | US#1,749/3,118 Sec#96/265 |
| FCF Yield | -10.11% | US—/3,118 Sec—/265 |
| Profitability | ||
| ROE | -63.45% | US#2,720/3,118 Sec#179/265 |
| ROA | -52.34% | US#2,991/3,118 Sec#219/265 |
| Financial Health | ||
| Debt Ratio | 21.23% | US#238/3,118 Sec#80/265 |
| Total Debt | $98M | US#2,439/3,118 Sec#121/265 |
| FCF | $-139M | US#2,700/3,118 Sec#173/265 |
| Cash | $138M | US#2,001/3,118 Sec#140/265 |
| Current Ratio | 34.46x | US#72/3,118 Sec#8/265 |
| Performance | ||
| 1Y Return | -61.99% | US#2,930/3,118 Sec#239/265 |
| 1M Return | -34.28% | US#2,953/3,118 Sec#245/265 |
| From 52W High | -67.41% | US#2,868/3,118 Sec#226/265 |
| 1Y MDD | -67.19% | US#2,761/3,118 Sec#209/265 |
| Trading | ||
| Volume | 4,220,134 shares | US#525/3,118 Sec#40/265 |
| Trading Value | $69M | US#1,042/3,118 Sec#60/265 |
| Per Share | ||
| EPS | $-3.95 | US—/3,118 Sec—/265 |
| BPS | $6.23 | US#2,172/3,118 Sec#108/265 |
Company Info
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.